Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio

DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Glioblastoma Multiforme Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

Some of the key facts of the Glioblastoma Multiforme Market Report:

• The Glioblastoma Multiforme (GBM) market size is projected to grow from approximately USD 900 million in 2025 to nearly USD 4.8 billion by 2036, registering a CAGR of 13.2% during the forecast period from 2026 to 2036.

• In October 2025, The U.S. Food and Drug Administration awarded orphan drug designation to an exosome-based therapy being developed by Exousia Pro as a potential treatment for patients with glioblastoma multiforme.

• In August 2025, A new clinical study targeting patients with recurrent glioblastoma multiforme, an aggressive and hard-to-treat brain tumor, received clearance from the U.S. Food and Drug Administration. Starlight Therapeutics announced that its investigational new drug (IND) application has been approved for a Phase Ib/2a trial evaluating the combination of its novel candidate STAR-001 (LP-184) with the FDA-approved drug spironolactone. The trial will specifically enroll adult patients whose GBM has progressed following initial treatment.

• In June 2025, Diakonos Oncology, a U.S.-based biotechnology firm, secured $20 million through a private placement of Simple Agreements for Future Equity (SAFE) to accelerate its Phase II glioblastoma trial of dubodencel. The investment will also support the expansion of its clinical portfolio into additional indications, including refractory melanoma. The funding round included participation from new backers such as Baylor College of Medicine and the Brain Tumor Investment Fund, alongside existing investors, including the company’s CEO, Mike Wicks.

• In May 2025, According to a press release from Roswell Park Comprehensive Cancer Center, the Phase 2b SURVIVE study (NCT05163080) evaluating SurVaxM, a cancer vaccine, in patients with newly diagnosed glioblastoma will proceed based on interim trial data analysis.

• The United States contributes the highest market size in the 7MM. The total market size of glioma in the United States was around USD 900 million in 2025.

• Among the current therapies for glioma Optune ± TMZ captured the highest revenue in 2025 in the United States.

• According to DelveInsight’s estimates, the total number of incident cases of GBM in the 7MM was nearly 38,000 cases in 2025 and is projected to increase during the forecasted period.

• The total number of incident cases of GBM in the United States was nearly 15,500 in 2025.

• In 2025, BRAF V600E mutation cases accounted for the largest share of incident GBM cases in the United States.

• The total number of cases of Primary GBM was found to be the highest than Secondary GBM in the United States and was estimated to be nearly 14,000 in 2025

• GBM is associated with a higher disease burden in men than in women. Roughly 60% of the total GBM cases in the United States are men. When compared with the adults, Glioblastoma in children is relatively rare.

• Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics and others

• Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others

• The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females

• The Glioblastoma Multiforme market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.

Glioblastoma Multiforme Overview

Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant brain tumor, classified as a grade IV astrocytoma. It originates from the supportive tissue of the brain called glial cells, specifically astrocytes. GBM is highly invasive, infiltrating nearby brain tissue, and rapidly growing, often leading to significant neurological symptoms and poor prognosis.

To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glioblastoma Multiforme Market Forecast

Glioblastoma Multiforme Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glioblastoma Multiforme Epidemiology Segmentation:

The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Glioblastoma Multiforme

• Prevalent Cases of Glioblastoma Multiforme by severity

• Gender-specific Prevalence of Glioblastoma Multiforme

• Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Epidemiology Forecast

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Glioblastoma Multiforme Therapies and Key Companies

• TEMODAR/TEMODAL (temozolomide): Merck

• AV-GBM-1: Aivita Biomedical and TAE Life Sciences

• Eflornithine: Orbus Therapeutics

• Dordaviprone (ONC201): Chimerix

• Durvalumab: AstraZeneca

• DNX-2401: DNAtrix

• ONC201: Chimerix

• DCVax-L: Northwest Therapeutics

• Regorafenib: Bayer

• Paxalisib(GDC-0084): Kazia Therapeutics

• AV-GBM-1: Aivita Biomedical

• MDNA55: Medicenna Therapeutics

• VAL-083: Kintara Therapeutics

Discover more about therapies set to grab major Glioblastoma Multiforme market share @ Glioblastoma Multiforme Treatment Landscape

Glioblastoma Multiforme Market Strengths

• Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for GBM

• Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed

Glioblastoma Multiforme Market Opportunities

• Numerous failed clinical trials suggest combination therapies willikely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties

• Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression

Scope of the Glioblastoma Multiforme Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Glioblastoma Multiforme Companies: Bayer, VBL Therapeutics, AstraZeneca, DNAtrix,Kintara Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, AivitaBiomedical, Medicenna Therapeutics, Immunomic Therapeutics, Treovir, Istari Oncology,Inovio Pharmaceuticals, Northwest Biotherapeutics, and others

• Key Glioblastoma Multiforme Therapies: Durvalumab, DNX-2401, ONC201, DCVax-L, Regorafenib, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others

• Glioblastoma Multiforme Therapeutic Assessment: Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies

• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Glioblastoma Multiforme Unmet Needs, KOL’s views, Analyst’s views, Glioblastoma Multiforme Market Access and Reimbursement

To know more about Glioblastoma Multiforme companies working in the treatment market, visit @ Glioblastoma Multiforme Clinical Trials and Therapeutic Assessment

Table of Contents

1. Glioblastoma Multiforme Market Report Introduction

2. Executive Summary for Glioblastoma Multiforme

3. SWOT analysis of Glioblastoma Multiforme

4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance

5. Glioblastoma Multiforme Market Overview at a Glance

6. Glioblastoma Multiforme Disease Background and Overview

7. Glioblastoma Multiforme Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioblastoma Multiforme

9. Glioblastoma Multiforme Current Treatment and Medical Practices

10. Glioblastoma Multiforme Unmet Needs

11. Glioblastoma Multiforme Emerging Therapies

12. Glioblastoma Multiforme Market Outlook

13. Country-Wise Glioblastoma Multiforme Market Analysis (2022–2036)

14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies

15. Glioblastoma Multiforme Market Drivers

16. Glioblastoma Multiforme Market Barriers

17. Glioblastoma Multiforme Appendix

18. Glioblastoma Multiforme Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio